LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Akcijų sąrašas・Compugen Ltd

Compugen Ltd

Uždarymo kaina

1.52 -5.59

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.48

Max

1.6

Pagrindiniai rodikliai
By Trading Economics
Pajamos	363K -7M
Pardavimai	634K 1.9M
Pelno marža	-369.064
Darbuotojai	74
EBITDA	420K -6.9M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+150% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-10M 146M
Ankstesnė atidarymo kaina	7.11
Ankstesnė uždarymo kaina	1.52

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

1.25 / 1.48 Palaikymas ir pasipriešinimas

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-12 16:42; UTC

Įsigijimai, susijungimai, perėmimai

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

2025-12-12 23:49; UTC

Įsigijimai, susijungimai, perėmimai

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

2025-12-12 22:52; UTC

Rinkos pokalbiai

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

2025-12-12 22:32; UTC

Uždarbis

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025-12-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-12 20:45; UTC

Uždarbis

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

2025-12-12 20:41; UTC

Rinkos pokalbiai

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

2025-12-12 20:20; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

2025-12-12 19:23; UTC

Uždarbis

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

2025-12-12 18:35; UTC

Įsigijimai, susijungimai, perėmimai

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

2025-12-12 18:33; UTC

Įsigijimai, susijungimai, perėmimai

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

2025-12-12 18:31; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

2025-12-12 17:49; UTC

Uždarbis

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

2025-12-12 17:34; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

2025-12-12 17:33; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Closing of the Transaction Is Expected in the First Half of 2026

2025-12-12 17:33; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

2025-12-12 17:32; UTC

Įsigijimai, susijungimai, perėmimai

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

2025-12-12 17:31; UTC

Įsigijimai, susijungimai, perėmimai

Orange to Buy the Stake for EU4.25B in Cash

2025-12-12 17:24; UTC

Rinkos pokalbiai

Argentina Predicts Record Wheat Crop -- Market Talk

2025-12-12 17:20; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-12-12 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-12 17:18; UTC

Rinkos pokalbiai

Uždarbis

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

2025-12-12 17:09; UTC

Rinkos pokalbiai

Broadcom Investors Were Primed to Sell Shares -- Market Talk

2025-12-12 17:09; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-12 16:47; UTC

Rinkos pokalbiai

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

2025-12-12 16:39; UTC

Rinkos pokalbiai

Supply Limits, Geopolitical Risk to Support Crude in 2026 -- Market Talk

2025-12-12 16:27; UTC

Įsigijimai, susijungimai, perėmimai

FTC Sues to Block Henkel's $725M Deal for Liquid Nails From PE Firm -- 2nd Update

2025-12-12 16:15; UTC

Uždarbis

At Costco, Lots of Pie but No Special Dividend. Why the Street Didn't Like the Earnings. -- Barrons.com

2025-12-12 15:35; UTC

Uždarbis

These Stocks Are Moving the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025-12-12 14:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

150% į viršų

12 mėnesių prognozė

Vidutinis 4 USD 150%

Aukščiausias 4 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Compugen Ltd akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.25 / 1.48Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.